Celecoxib attenuates hepatic cirrhosis through inhibition of epithelial-to-mesenchymal transition of hepatocytes

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 11, 2014, Pages 1932-1942

  Wen, Shi Lei ^a,b   Gao, Jin Hang ^b   Yang, Wen Juan ^a   Lu, Yao Yao ^a   Tong, Huan ^a   Huang, Zhi Yin ^a   Liu, Zhang Xu ^c   Tang, Cheng Wei ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Celecoxib; Cirrhosis; Epithelial to mesenchymal transition; Hepatic fibrosis; Hepatocyte

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; PYRAZOLE DERIVATIVE; SMAD PROTEIN; SULFONAMIDE; THIOACETAMIDE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DOWN REGULATION; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; EXPERIMENTAL LIVER CIRRHOSIS; GENETICS; LIVER CELL; LIVER CIRRHOSIS; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCYTES; LIVER CIRRHOSIS; LIVER CIRRHOSIS, EXPERIMENTAL; PYRAZOLES; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SMAD PROTEINS; SULFONAMIDES; THIOACETAMIDE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84912053730     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12641     Document Type: Article

References (48)

1. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu. Rev. Pathol. 2011; 6: 425-456.
2. Pellicoro A, Ramachandran P, Iredale JP. Reversibility of liver fibrosis. Fibrogenesis. Tissue. Repair. 2012; 5 (Suppl. 1): S26.
3. Jiao J, Friedman SL, Aloman C. Hepatic fibrosis. Curr. Opin. Gastroenterol. 2009; 25: 223-229.
4. Schuppan YPaD. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology. 2009; 50: 1294-1306.
5. Iredale J. Defining therapeutic targets for liver fibrosis: exploiting the biology of inflammation and repair. Pharmacol. Res. 2008; 58: 129-136.
6. Asahina K. Hepatic stellate cell progenitor cells. J. Gastroenterol. Hepatol. 2012; 27: 80-84.
7. Iwaisako K, Brenner DA, Kisseleva T. What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. J. Gastroenterol. Hepatol. 2012; 27: 65-68.
8. Ueno N, Takegoshi Y, Kamei D, Kudo I, Murakami M. Coupling between cyclooxygenases and terminal prostanoid synthases. Biochem. Biophys. Res. Commun. 2005; 338: 70-76.
9. Chandrasekharan NV, Simmons DL. The cyclooxygenases. Genome. Biol. 2004; 5: 241.
10. Rouzer CA, Marnett LJ. Cyclooxygenases: structural and functional insights. J. Lipid Res. 2009; 50 (Suppl.): S29-34.
11. Mohammed NA, El-Aleem SA, El-Hafiz HA, McMahon RFT. Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis. J. Clin. Pathol. 2004; 57: 350-354.
12. Jeong SW, Jang JY, Lee SH etal. Increased expression of cyclooxygenase-2 is associated with the progression to cirrhosis. Korean J. Intern. Med. 2010; 25: 364-371.
13. Botting RM. Inhibitors of cyclooxygenases: mechanisms, selectivity and uses. J. Physiol. Pharmacol. 2006; 57 (Suppl. 5): 113-124.
14. Flower RJ. The development of COX2 inhibitors. Nat. Rev. Drug. Discov. 2003; 2: 179-191.
15. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin. Pharmacokinet. 2000; 38: 225-242.
16. Paikh YH, Kim JK, Lee JI etal. Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats. Gut. 2009; 58: 1517-1527.
17. Gao JH, Wen SL, Yang WJ etal. Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis. PloS. ONE. 2013; 8: e69309.
18. Ishak K, Baptista A, Bianchi L etal. Histological grading and staging of chronic hepatitis. J. Hepatol. 1995; 22: 696-699.
19. Wisse E, Braet F, Duimel H etal. Fixation methods for electron microscopy of human and other liver. World. J. Gastroenterol. 2010; 16: 2851-2866.
20. Ayres-Silva Jde P, Manso PP, Madeira MR, Pelajo-Machado M, Lenzi HL. Sequential morphological characteristics of murine fetal liver hematopoietic microenvironment in Swiss Webster mice. Cell. Tissue. Res. 2011; 344: 455-469.
21. Novo E, di Bonzo LV, Cannito S, Colombatto S, Parola M. Hepatic myofibroblasts: a heterogeneous population of multifunctional cells in liver fibrogenesis. Int. J. Biochem. Cell. Biol. 2009; 41: 2089-2093.
22. Sicklick JK, Choi SS, Bustamante M etal. Evidence for epithelial-mesenchymal transitions in adult liver cells. Am. J. Physiol. Gastrointest. Liver. Physiol. 2006; 291: G575-583.
23. Wang R, Guo L, Wang P etal. Chemoprevention of cancers in gastrointestinal tract with cyclooxygenase 2 inhibitors. Curr. Pharm. Des. 2013; 19: 115-125.
24. Wasmuth HE, Tacke F, Trautwein C. Chemokines in liver inflammation and fibrosis. Semin. Liver. Dis. 2010; 30: 215-225.
25. Choi SS, Diehl AM. Epithelial-to-mesenchymal transitions in the liver. Hepatology. 2009; 50: 2007-2013.
26. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009; 119: 1420-1428.
27. Evans RD, Itoh Y. Analyses of MT1-MMP activity in cells. Methods. Mol. Med. 2007; 135: 239-249.
28. Inagaki Y, Okazaki I. Emerging insights into transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut. 2007; 56: 284-292.
29. Xu Jian, Lamouille S, Derynck R. TGF-β-induced epithelial to mesenchymal transition. Cell. Res. 2009; 19: 156-172.
30. Kaimori A, Potter J, Kaimori JY, Wang C, Mezey E, Koteish A. Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J. Biol. Chem. 2007; 282: 22089-22101.
31. Wells RG. Fibrogenesis. V. TGF-beta signaling pathways. Am. J. Physiol. Gastrointest. Liver. Physiol. 2000; 279: G845-850.
32. Sun Q, Prasad R, Rosenthal E, Katiyar SK. Grape seed proanthocyanidins inhibit the invasiveness of human HNSCC cells by targeting EGFR and reversing the epithelial-to-mesenchymal transition. PloS. ONE. 2012; 7: e31093.
33. Franco DL, Mainez J, Vega S etal. Snail1 suppresses TGF-beta-induced apoptosis and is sufficient to trigger EMT in hepatocytes. J. Cell. Sci. 2010; 123: 3467-3477.
34. Hulpiau P, van Roy F. Molecular evolution of the cadherin superfamily. Int. J. Biochem. Cell. Biol. 2009; 41: 349-369.
35. Cano A, Perez-Moreno MA, Rodrigo I etal. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell. Biol. 2000; 2: 76-83.
36. Le Bras GF, Taubenslag KJ, Andl CD. The regulation of cell-cell adhesion during epithelial-mesenchymal transition, motility and tumor progression. Cell. Adh. Migr. 2012; 6: 365-373. doi: 10.4161/cam.21326. Epub 2012 Jul 1.
37. Zeisberg M, Yang C, Martino M etal. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J. Biol. Chem. 2007; 282: 23337-23347.
38. Yang L, Jung Y, Omenetti A etal. Fate-mapping evidence that hepatic stellate cells are epithelial progenitors in adult mouse livers. Stem. Cells. 2008; 26: 2104-2113.
39. Taura K, Miura K, Iwaisako K etal. Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology. 2010; 51: 1027-1036.
40. Scholten D, Osterreicher CH, Scholten A etal. Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice. Gastroenterology. 2010; 139: 987-998.
41. Bastid J. EMT in carcinoma progression and dissemination: facts, unanswered questions, and clinical considerations. Cancer. Metastasis. Rev. 2012; 31: 277-283.
42. Adhim Z, Matsuoka T, Bito T etal. In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines. Br. J. Cancer. 2011; 105: 393-402.
43. Wang ZL, Fan ZQ, Jiang HD, Qu JM. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling. Carcinogenesis. 2013; 34: 638-646.
44. Ftahy MM, Latif NSA, Alalkamy EF, El-Batrawi FA, Galal AH, Khatab HM. Antifibrotic potential of a selective COX-2 inhibitor (celecoxib) on liver fibrosis in rats. Comp. Clin. Path. 2012; 22: 425-430.
45. McCormack PL. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs. 2011; 71: 2457-2489.
46. Hui AY, Leung W, Chan HL etal. Effect of celecoxib on experimental liver fibrosis in rat. Liver. Int. 2006; 26: 125-136.
47. Yu J, Hui A, Chu ES etal. The anti-inflammatory effect of celecoxib does not prevent liver fibrosis in bile duct-ligated rats. Liver. Int. 2009; 29: 25-36.
48. Liu H, Wei W, Li X. Celecoxib exacerbates hepatic fibrosis and induces hepatocellular necrosis in rats treated with porcine serum. Prostaglandins. Other. Lipid. Mediat. 2009; 88: 63-67.